Adams Clinical Expands Psychiatry Research with New Partnership
![Adams Clinical Expands Psychiatry Research with New Partnership](/images/blog/ihnews-Adams%20Clinical%20Expands%20Psychiatry%20Research%20with%20New%20Partnership.jpg)
Adams Clinical Expands Psychiatry Research Capabilities
Adams Clinical, LLC, a distinguished name in the neuroscience-focused clinical trial site network, recently announced an exciting partnership with InSite Clinical Research, a well-regarded clinical site located in the Dallas-Fort Worth metroplex. This strategic collaboration aims to significantly enhance Adams Clinical's capabilities in conducting inpatient psychiatric trials, especially focusing on complex conditions like schizophrenia.
Growing Inpatient Psychiatry Services
In line with this partnership, Adams Clinical is actively expanding its inpatient services at its existing sites in Watertown and Bronx. The Company anticipates these locations will commence screening inpatient participants in the near future, thereby reinforcing its leading position in outpatient psychiatry and trials related to Alzheimer's disease prevention and treatment.
Insights from Leadership
Nelson Rutrick, the CEO of Adams Clinical, highlights the importance of this partnership, stating, "This expansion adds a crucial dimension to our business. InSite brings a wealth of experience in conducting trials for schizophrenia, bipolar disorder, and substance use disorders. The expertise of Dr. Shiwach and his team is recognized across the pharmaceutical and biotech industries for their leadership in acute schizophrenia trials, which makes this collaboration particularly valuable."
Expert Contributions and Future Growth
Mehran Ahmed from InTandem Capital Partners also expressed enthusiasm about the partnership, noting InSite's proven track record in identifying participants for trials in this important category. The collaboration aims to further bolster InSite's already strong capabilities.
Dr. Raj Shiwach, Principal Investigator at InSite, shared his excitement about joining the Adams Clinical network, emphasizing the opportunity to leverage his clinical expertise to enhance trial opportunities for the diverse psychiatric and neurological populations in Texas.
Partnership Outcomes and Strategic Decisions
Dr. Steve Brannan, an expert in schizophrenia drug development, underscored the critical need for new therapies in this field. He mentioned, "The anticipated rise in effective treatments necessitates an increase in high-quality research sites that can conduct both inpatient and outpatient psychiatry trials. The inclusion of InSite and the establishment of inpatient units at Adams' Boston and New York locations reflect a strategic alignment with the needs of pharmaceutical and biotech sponsors."
Recent Growth and Expansions
This partnership is one part of a series of strategic steps taken by Adams Clinical throughout this year, which includes enhancing site capacities through the establishment of new locations in New York City, collaborating with Davis Clinical in the Bronx, and Berman Clinical in Harlem.
About Adams Clinical
Adams Clinical has established itself as a premier network known for its rapid enrollment and data quality in clinical trials targeted at disorders affecting the central nervous system. Their sites, located in vibrant and diverse communities throughout the United States, focus on providing high-quality evidence generation essential for pharmaceutical and biotech companies, as well as CROs.
About InTandem Capital Partners
InTandem Capital Partners is a private equity firm dedicated to investing in healthcare services companies. They pride themselves on working closely with business management teams to enhance growth and create substantial value in the healthcare landscape. Their focus aligns with the Healthcare Quintuple Aim, emphasizing improved patient and provider experiences, superior clinical outcomes, health equity, and cost-effective care delivery.
Frequently Asked Questions
What is the main purpose of the partnership between Adams Clinical and InSite Clinical?
The partnership aims to enhance Adams Clinical's capabilities in conducting inpatient psychiatric trials, particularly focusing on conditions like schizophrenia.
Which locations are involved in the expansion of inpatient psychiatry services?
The expansion will take place at Adams Clinical's existing sites in Watertown, MA, and Bronx, NY.
Who is overseeing the implementation of the new trials at InSite?
Dr. Raj Shiwach, who is the Principal Investigator at InSite, will oversee the trial implementation.
What kind of expertise does InSite bring to the partnership?
InSite offers deep expertise in conducting trials for schizophrenia and related psychiatric disorders, making it a valuable addition to Adams Clinical's network.
What strategic steps has Adams Clinical taken recently?
Adams Clinical has doubled its site capacity by opening new locations in New York City and strengthening existing partnerships.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.